Skip to main content

Neurocrine Biosciences Inc

NBIX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000914475

In the last 90 days, Neurocrine Biosciences Inc insiders filed 0 open-market purchases and 7 sales; 782 institutions reported holding it in 13F filings for Q2 2026, worth $17.0B in total; no superinvestor holds it.

13F holders, Q3 2025

Institutional positions in Neurocrine Biosciences Inc as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
650
+71 vs. Q2 2025
Shares held
97.2M
−711.9K (−0.7%) vs. Q2 2025
Total value
$13.6B
+$1.33B (+10.8%) vs. Q2 2025
New holders
121
220 more added
Sold out
50
219 more reduced

8 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q2 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting NBIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2025: 650 institutions
Q1 2021: 421 institutionsQ2 2021: 409 institutionsQ3 2021: 397 institutionsQ4 2021: 406 institutionsQ1 2022: 426 institutionsQ2 2022: 439 institutionsQ3 2022: 466 institutionsQ4 2022: 530 institutionsQ1 2023: 488 institutionsQ2 2023: 457 institutionsQ3 2023: 513 institutionsQ4 2023: 555 institutionsQ1 2024: 591 institutionsQ2 2024: 595 institutionsQ3 2024: 577 institutionsQ4 2024: 602 institutionsQ1 2025: 587 institutionsQ2 2025: 587 institutionsQ3 2025: 650 institutionsQ4 2025: 733 institutionsQ1 2026: 700 institutionsQ2 2026: 782 institutions
Value heldQ3 2025: $13.6B
Q1 2021: $9.25BQ2 2021: $8.89BQ3 2021: $8.66BQ4 2021: $7.59BQ1 2022: $8.45BQ2 2022: $8.74BQ3 2022: $9.60BQ4 2022: $10.7BQ1 2023: $9.22BQ2 2023: $8.64BQ3 2023: $10.4BQ4 2023: $12.2BQ1 2024: $12.9BQ2 2024: $12.9BQ3 2024: $10.7BQ4 2024: $12.9BQ1 2025: $10.6BQ2 2025: $12.4BQ3 2025: $13.6BQ4 2025: $14.1BQ1 2026: $13.2BQ2 2026: $17.0B
Institutions holding NBIX and their total value by quarter
QuarterHoldersValue
Q2 2026782$17.0B
Q1 2026700$13.2B
Q4 2025733$14.1B
Q3 2025650$13.6B
Q2 2025587$12.4B
Q1 2025587$10.6B
Q4 2024602$12.9B
Q3 2024577$10.7B
Q2 2024595$12.9B
Q1 2024591$12.9B
Q4 2023555$12.2B
Q3 2023513$10.4B
Q2 2023457$8.64B
Q1 2023488$9.22B
Q4 2022530$10.7B
Q3 2022466$9.60B
Q2 2022439$8.74B
Q1 2022426$8.45B
Q4 2021406$7.59B
Q3 2021397$8.66B
Q2 2021409$8.89B
Q1 2021421$9.25B

Institutions, Q3 2025

Shares, value and share of portfolio for each institution holding Neurocrine Biosciences Inc; share changes are against Q2 2025.

Institutions holding NBIX in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Norges Bank––––Not filed
E Fund Management Co., Ltd.––––Not filed
CIBC World Markets Corp––––Not filed
Avantax Advisory Services, Inc.––––Not filed
First Horizon Advisors, Inc.––––Not filed
Talon Private Wealth, LLC––––Not filed
Legacy Investment Solutions, LLC––––Not filed
Parkworth Wealth Management, Inc.––––Not filed